drug conjugate News
-
Araris Biotech AG to Present at the H.C. Wainwright Preclinical Cancer Drug Discovery Virtual Conference
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will be presenting at the H.C. Wainwright Preclinical Cancer Drug Discovery: Emerging Targets and Modalities virtual conference on June 29, 2022. The pre-recorded company presentation will be included in Part I – Antibody-Drug Conjugates (ADCs), and virtual ...
-
Araris Biotech AG to Present at Informa Connect’s Next Generation Protein Therapeutics Summit
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect. The presentation will highlight Araris’ proprietary linker technology, which enables the conjugation of ...
-
BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the ...
By BOC Sciences
-
Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022
Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022. This marks the second time that Synaffix’ groundbreaking ADC platform ...
By Synaffix BV
-
Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will present data on Araris’ linker technology at the 13th Annual World ADC Conference in San Diego. The poster presentation, titled, "Inducing complete and long-lasting tumor eradications of a nectin-4 ADC generated with a novel linker technology,” ...
-
Araris Biotech Closes $24 Million Financing Round
Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the ...
-
PeptiDream Inc. in peptide drug conjugate (PDC) collaboration in Novartis
Expanding on their long-standing macrocyclic peptide discovery alliance between the two companies since 2012, Japan-based PeptiDream announced last week that their proprietary Peptide Discovery Platform System (PDPS) technology will be used to identify novel macrocyclic/constrained peptides as PDCs against multiple targets of interest selected by Novartis. Under the agreement, Novartis will have ...
By IMAPAC
-
Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer. “We are thrilled to welcome Filippo to our executive team,” said Philipp Spycher, Ph.D., chief executive officer of Araris Biotech. “Filippo’s extensive experience in ...
-
Araris Biotech AG to Present at 12th Annual World ADC London 2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates ...
-
Synaffix Licenses CliCr Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ...
By Synaffix BV
-
Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal
Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload) Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total ...
By Synaffix BV
-
Araris Biotech AG to Present at 12th Annual World ADC London 2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates ...
-
Synaffix Inks $586m Deal with MacroGenics to Enable Next Generation ADCs
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies MacroGenics to combine proprietary antibody and bispecific DART® technology with Synaffix’s linker-payload technologies to develop up to three next generation conjugates Total potential deal value of up to $586 million, plus royalties on commercial sales Synaffix B.V., a biotechnology company ...
By Synaffix BV
-
Creative Peptides Released One-Stop Solution for All Peptide Drug Conjugate Needs
Peptide drug conjugate (PDC) is emerging as a novel type of conjugate drug, showing advantageous features over antibody-drug conjugates (ADCs). As a dedicated peptide manufacturer, Creative Peptides provides a one-stop solution for all peptide drug bioconjugation needs to help pharmaceutical clients bring more PDCs to the market. Structurally, PDC mainly contains three elements—cytotoxin, ...
-
Biopharma PEG: Your Premier Source for High-Purity Monodispersed PEGs
Biopharma PEG, a leading provider of innovative solutions for the pharmaceutical industry, is proud to announce an extensive inventory of monodispersed PEGs (Polyethylene Glycols) that cater to a wide range of applications, including Antibody Drug Conjugates (ADCs), PROTACs, drug delivery systems, and more. Our comprehensive collection includes mPEG36-NH2, NH2-PEG24-COOH, mPEG11-SPA, ...
-
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston. The presentation will be accessible ...
-
Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E-Based ADCs
Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020) Synaffix B.V., a biotechnology company ...
By Synaffix BV
-
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wedbush PacGrow Healthcare Conference’s panel discussion, “ADCs – Take Me to Your Tumor” on Wednesday, August 10, 2022, ...
-
Technical Talk: Explore Next-Generation Nuclear Localization Signal Therapeutics
Creative Biolabs, as a top-ranked solution provider of antibody-drug conjugate, scheduled a webinar about improved nuclear localization signal-therapeutics, which went live on January 21, 2022. Antibody-drug conjugate (ADC) has gained booming attention in the past 2021, with multiple international strategic purchases and breakthrough results of both preclinical and clinical trials. As a forefront ...
-
CELLVIE wins in the category for Health Solutions at the Falling Walls Summit
Falling Walls is a unique global hub connecting science, business and society. The purpose is to shape the future of humanity by giving a stage to impact-oriented ideas and discoveries, driven by the dedication for creating breakthroughs across borders and disciplines. As a vessel for the world-changing spirit of 1989 in and beyond Berlin, it is on a relentless pursuit to find out: Which are the ...
By cellvie Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you